Return On Equity of Avalo Therapeutics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Avalo Therapeutics, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2025 was -88%, a 372% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Return On Equity for 2024 was -503%, a 65% increase from 2023.
  • Avalo Therapeutics, Inc. annual Return On Equity for 2023 was -1440%, a 208% decline from 2022.
  • Avalo Therapeutics, Inc. annual Return On Equity for 2022 was 1328%.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Avalo Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 -88% -121% -372% 01 Jul 2025 30 Sep 2025
Q2 2025 -48% -188% -135% 01 Apr 2025 30 Jun 2025
Q1 2025 111% -475% -81% 01 Jan 2025 31 Mar 2025
Q4 2024 -503% +937% +65% 01 Oct 2024 31 Dec 2024
Q3 2024 33% -1371% -98% 01 Jul 2024 30 Sep 2024
Q2 2024 139% -239% -63% 01 Apr 2024 30 Jun 2024
Q1 2024 586% +116% +25% 01 Jan 2024 31 Mar 2024
Q4 2023 -1440% -2767% -208% 01 Oct 2023 31 Dec 2023
Q3 2023 1404% +2356% 01 Jul 2023 30 Sep 2023
Q2 2023 378% +828% 01 Apr 2023 30 Jun 2023
Q1 2023 470% +802% 01 Jan 2023 31 Mar 2023
Q4 2022 1328% +1613% 01 Oct 2022 31 Dec 2022
Q3 2022 -952% -682% -252% 01 Jul 2022 30 Sep 2022
Q2 2022 -449% -188% -72% 01 Apr 2022 30 Jun 2022
Q1 2022 -332% -133% -67% 01 Jan 2022 31 Mar 2022
Q4 2021 -286% -103% -57% 01 Oct 2021 31 Dec 2021
Q3 2021 -270% -134% -98% 01 Jul 2021 30 Sep 2021
Q2 2021 -261% -133% -105% 01 Apr 2021 30 Jun 2021
Q1 2021 -199% -55% -38% 01 Jan 2021 31 Mar 2021
Q4 2020 -182% -102% -127% 01 Oct 2020 31 Dec 2020
Q3 2020 -136% -20% -17% 01 Jul 2020 30 Sep 2020
Q2 2020 -128% +88% +41% 01 Apr 2020 30 Jun 2020
Q1 2020 -144% +67% +32% 01 Jan 2020 31 Mar 2020
Q4 2019 -80% +110% +58% 01 Oct 2019 31 Dec 2019
Q3 2019 -116% +49% +29% 01 Jul 2019 30 Sep 2019
Q2 2019 -216% -240% -982% 01 Apr 2019 30 Jun 2019
Q1 2019 -211% -262% -512% 01 Jan 2019 31 Mar 2019
Q4 2018 -190% -280% -311% 01 Oct 2018 31 Dec 2018
Q3 2018 -165% -378% -177% 01 Jul 2018 30 Sep 2018
Q2 2018 24% +1345% 01 Apr 2018 30 Jun 2018
Q1 2018 51% +946% 01 Jan 2018 31 Mar 2018
Q4 2017 90% +522% 01 Oct 2017 31 Dec 2017
Q3 2017 213% +476% 01 Jul 2017 30 Sep 2017
Q2 2017 -1321% -2299% -235% 01 Apr 2017 30 Jun 2017
Q1 2017 -895% 01 Jan 2017 31 Mar 2017
Q4 2016 -432% 01 Oct 2016 31 Dec 2016
Q3 2016 -263% 01 Jul 2016 30 Sep 2016
Q2 2016 979% 01 Apr 2016 30 Jun 2016

Avalo Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -503% +937% +65% 01 Jan 2024 31 Dec 2024
2023 -1440% -2767% -208% 01 Jan 2023 31 Dec 2023
2022 1328% +1613% 01 Jan 2022 31 Dec 2022
2021 -286% -103% -57% 01 Jan 2021 31 Dec 2021
2020 -182% -102% -127% 01 Jan 2020 31 Dec 2020
2019 -80% +110% +58% 01 Jan 2019 31 Dec 2019
2018 -190% -280% -311% 01 Jan 2018 31 Dec 2018
2017 90% +522% 01 Jan 2017 31 Dec 2017
2016 -432% 01 Jan 2016 31 Dec 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.